‹ Back
NEW
WHO QRM 2026 versus WHO QRM 2003
WHO guidelines on quality risk management
General information
Valid from 23.10.2026
Directives or regulations
none
Handling area
Give feedback
In most countries compliance with good manufacturing practices (GMP), medicines regulatory activities and inspections, together with supply chain controls throughout the product life-cycle, provide good assurance that risks are largely controlled. However, where control is less effective, patients may be put at risk through the production of medicines of inadequate quality. Quality risk management (QRM) is a process that is relevant to all countries and should provide a rationale to understand risk and mitigate it through appropriate and robust controls.
To protect patients in terms of quality, safety and efficacy of medicines, international medicines regulatory authorities (MRAs) are recommending pharmaceutical manufacturers to adopt a risk-based approach to the life-cycle of a pharmaceutical product. QRM is the overall and continuing process of appropriately managing risks to product quality throughout the product's life-cycle in order to optimize its benefit–risk balance. It is a systematic process for the assessment, control, communication and review of risks to the quality of the pharmaceutical product. It can be applied both proactively and retrospectively.
Related products
Healthcare, ISO
ISO 8637-1 2024 Versus ISO 8637-1 2017
Extracorporeal systems for blood purification Part 1: Haemodialysers, haemodiafilters, haemofilters and haemoconcentrators
Healthcare, ISO
ISO 10993-6:2026 vs ISO 10993-6:2016
Biological evaluation of medical devices Part 6: Tests for local effects after implantation
Healthcare, ISO
ISO 10993-7:2026 versus ISO 10993-7:2018+A1:2022
Biological evaluation of medical devices Part 7: Ethylene oxide sterilization residuals
Aerospace, Healthcare, ISO
Healthcare
WHO QRM 2026 versus WHO QRM 2003
Price range: $45.00 through $115.00
WHO guidelines on quality risk management